pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
Quick answer
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at birth in full-term newborns. NovaPharmaNews links 40 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (25), approved (6), phase 2 (5).
Company snapshot
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect m
- 40 active pipeline program(s) linked via ClinicalTrials.gov.
- 40 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Novo Nordisk A/S. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
AI Accelerates Novo Nordisk's Parkinson’s Cell Therapy
- approval
EMA Endorses Novo Nordisk's Wegovy for Weight Loss
- approval
US FDA Proposes New Regulations on Weight-Loss Drug Compounding
- approval
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
- trial_data
Novo Nordisk supply of Wegovy stabilizes as new capacity comes online
- trial_data
Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends
- approval
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
- approval
Novo wins UK approval as race to launch weight-loss pill intensifies
Recent coverage
Weight Loss Medications in 2026: GLP-1 Market Shift
Novo wins UK approval as race to launch weight-loss pill intensifies
Novo Nordisk won UK approval for its oral Wegovy weight-loss pill, making the UK the first European market to allow access. The decision strengthens Novo’s lead in the oral GLP-1 race as Eli Lilly advances orforglipron.
Novo Nordisk supply of Wegovy stabilizes as new capacity comes online
Novo Nordisk says Wegovy supply is stabilizing as FDA-determined shortages of Wegovy and Ozempic are resolved. The company is also investing $4.1 billion to expand manufacturing capacity in Clayton, North Carolina.
Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends
Novo Nordisk supply Wegovy stabilizes as the FDA says the shortage of Wegovy and Ozempic is resolved. The change follows new and planned manufacturing capacity, with implications for access, competition, and BD strategy.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Novo Nordisk A/S.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Novo Nordisk A/S.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Novo Nordisk A/S?
-
Is Novo Nordisk A/S publicly traded?
-
What drugs does Novo Nordisk A/S develop or market?
-
What are the latest developments for Novo Nordisk A/S?
-
What therapeutic areas does Novo Nordisk A/S focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.